Tau workflow comparison images
700 images
- EndpointFlortaucipir SUVR agreement against an MR-based method
- Populationsyngo.via MI Workflows; Scenium; syngo MBF
- Tested versionsyngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30
FDA-cleared profile
Siemens Medical Solutions USA, Inc. · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))
Authorized purpose: syngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30 support PET, SPECT, nuclear-medicine, CT, and MR viewing, quantification, analysis, longitudinal comparison, organ segmentation, tumor-burden assessment, tau analysis, myocardial blood-flow analysis, and selected radiotherapy-planning support.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: syngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30 support PET, SPECT, nuclear-medicine, CT, and MR viewing, quantification, analysis, longitudinal comparison, organ segmentation, tumor-burden assessment, tau analysis, myocardial blood-flow analysis, and selected radiotherapy-planning support.
Evidence takeaway. Evidence from the reviewed source record: K232000 reports software verification, quantitative organ-segmentation testing, and agreement testing for tau quantification. All organs met either Dice or average symmetric surface-distance criteria, and tau SUVR comparisons on more than 700 ADNI flortaucipir images showed good correlation and agreement with an MR-based method; no clinical study was performed.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
The exact packet supports these outputs and does not expose a myocardial-blood-flow result description.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
The replacement uses the exact packet's clinical-testing statement and listed segmentation-accuracy factors and removes the unsupported blanket professional-review sentence.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.
Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.
700 images
K232000
Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesBuild a local total-cost and value model; do not infer reimbursement from FDA clearance.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: PET or nuclear-medicine functional data plus optional CT or MR anatomical datasets from one or more time points.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-19 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF
Source context, not route validation: DICOM transfers into a syngo.via server/client environment with configurable automatic import, manual media import, reporting, and storage; validate PET/SPECT/CT/MR objects, SUV harmonization, time points, output routing, and OpenApps launch behavior.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-03 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF · syngo.via molecular imaging reading software
Source context, not route validation: Software-only applications installed on common IT hardware as part of the syngo.via client/server system; exact licenses and supported platform versions must be mapped locally.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-03 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF · syngo.via molecular imaging reading software
Source context, not route validation: Viewing, manipulation, quantification, analysis and comparison of PET/NM and CT/MR images; harmonized PET SUV values; organ segmentation and organ-specific tumor-burden features; and tau PET quantification with cortical and background SUVR calculations.
Scope: Exact FDA submission. The exact packet supports these outputs and does not expose a myocardial-blood-flow result description.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-19 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF
Unresolved route: Viewing, manipulation, quantification, analysis and comparison of PET/NM and CT/MR images; harmonized PET SUV values; organ segmentation and organ-specific tumor-burden features; and tau PET quantification with cortical and background SUVR calculations.
Scope: Exact FDA submission. The exact packet supports these outputs and does not expose a myocardial-blood-flow result description.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-19 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Map the installed model, build, options, population, anatomy, inputs, and outputs to K232000 before acceptance.
exact submission · checked 2026-09-03Later product-family features are not evidence that this cleared release includes them.
DICOM transfers into a syngo.via server/client environment with configurable automatic import, manual media import, reporting, and storage; validate PET/SPECT/CT/MR objects, SUV harmonization, time points, output routing, and OpenApps launch behavior.
exact submission · checked 2026-09-03Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Clinical testing was not conducted for K232000. Segmentation can be affected by scanner calibration, reconstruction, contrast protocol, dose, motion, anatomy, organ size, orientation, and user skill; all quantitative outputs require professional review.
exact submission · checked 2026-09-03Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Clinical testing was not conducted for K232000. Segmentation can be affected by scanner calibration, reconstruction, contrast protocol, dose, motion, anatomy, organ size, orientation, and user skill; all quantitative outputs require professional review.
exact submission · checked 2026-09-03Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The refreshed discovery snapshot contains 18 PubMed and 2 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 18 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
8 sources - 3 history items
Scope: modality, anatomy, intendedUsers, input, evidenceSummary, purpose, output, limitations, clinicalUse
Scope: regulatoryIdentity, modalityContext
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: coverage, codingContext
Scope: recallDiscovery, nativeSubmissionMatching
Scope: productFamily, workflowRole, integration, deployment, implementationCapabilities, currentCommercialContext
Scope: security
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Siemens Medical Solutions USA, Inc.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Siemens Medical Solutions USA, Inc.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
Shanghai United Imaging Healthcare Co., Ltd.
Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Shanghai United Imaging Healthcare Co., Ltd.
Authorized purpose: uMI Panorama GS combines 148 cm axial-field-of-view PET with CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and registered or fused PET/CT images supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation in oncology, cardiology, neurology, inflammation, infection, and other disorders. The CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history